| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Leerink Partners analyst Daina Graybosch downgrades Century Therapeutics (NASDAQ:IPSC) from Outperform to Market Perform and...
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate o...
- SEC Filing
Chardan Capital analyst Geulah Livshits maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target ...
Century Therapeutics (NASDAQ:IPSC) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of ...